Seroquel Weight Gain Problems Kept From Doctors

Internal documents disclosed during the litigation over Seroquel suggest that AstraZeneca continued to promote the antipsychotic drug as weight neutral, years after clinical evidence demonstrated significant Seroquel weight gain problems for users, which could lead to diabetes and other serious side effects.

A 2001 letter from a marketing official revealed that the pharmaceutical giant had a global strategy aimed at casting Seroquel as “weight neutral”, according to a report by Bloomberg News. This letter was written four years after the drug company’s own research found “clinically significant” weight gain among users of Seroquel.

The evidence was presented during a pretrial examination of John Patterson, a former AstraZeneca executive who reported directly to the company’s CEO. The 2001 letter appeared to directly contradict a 1997 email from one of AstraZeneca’s doctors that reported 45% of patients gained significant weight with Seroquel in a year.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Seroquel (quetiapine fumarate) is an atypical-antipsychotic that is a top selling drug for AstraZeneca, generating nearly $4.45 billion in sales in 2008. Approved by the FDA in 1997 for the treatment of schizophrenia, it is also commonly used off-label for treatment of anxiety, obsessive dementia, compulsive disorders and autism. Seroquel has been used by more than 19 million people worldwide.

Thousands of people have filed a Seroquel lawsuit against AstraZeneca alleging that the drug maker failed to adequately warn about the increased risk of diabetes, which is caused by the drug’s weight gain side effects. Among other things, plaintiffs argue that AstraZeneca actively concealed the diabetes risk with Seroquel when asked by U.S. doctors, even though they knew or should have known that there was a connection.

All federal Seroquel cases are consolidated for pretrial litigation in an MDL, or multidistrict litigation, that is centralized in the U.S. District Court for the Middle District of Florida.

Other documents produced during Patterson’s testimony were used to used to suggest the company was promoting Seroquel for uses that had not been determined to be safe and effective by the FDA. A “Seroquel Strategy Summary” in 2000 reportedly described off label promotion as a goal.

While doctors are free to prescribe drugs for non-approved uses, it is illegal under current federal regulations for a drug company to promote their medications for such “off-label” use. Patterson estimated during his testimony that off-label use accounted for 30% to 40% of Seroquel sales, and admitted that percentage could be higher.

or off-label uses.

3 Comments

  • DianeJuly 24, 2014 at 7:00 pm

    I have concerns about Seroquel in which I was prescribed for years please contact me about this Thank You,

  • BrandyFebruary 4, 2010 at 6:10 am

    The weight gain was something I was completely unaware of. I gained two sizes, before I realized what it was making me gain weight. I am off of the drug now.

  • BarbaraNovember 22, 2009 at 9:56 am

    At the time, my son was 7 years old. Here in Alaska, subsequently, Robert has been diagnosed bi-polar disorder and was subscribed Seroquel for over a year. He put on the weight, but, the bad thing about this, the doctor he was seeing at the time, was passed out most of the time. Only 7 years old, was taking 4 times a day?!

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.